Haiyi Jiang

发表

Alinka Lepine-Szily, P. N. de Faria, E. Martinez-Quiroz, 2017 .

Conception and Current Progress of China In-Service Pressure Equipment Inspection and Assessment Regulation and Standard System

Hui Wang, Jin Shi, Guodong Jia, 2010 .

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Masahiro Fukuoka, Haiyi Jiang, Kazuhiko Nakagawa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

You Lu, Haiyi Jiang, Kazuhiko Nakagawa, 2015, The Lancet. Oncology.

Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

Koichi Goto, Masahiro Fukuoka, Nobuyuki Yamamoto, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

Kenji Eguchi, Masahiro Tsuboi, Masahiro Fukuoka, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.